Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
Anne C. Goldberg, Lawrence A. Leiter, Erik S.G. Stroes, et al.
JAMA (2019) Vol. 322, Iss. 18, pp. 1780-1780
Open Access | Times Cited: 392

Showing 1-25 of 392 citing articles:

Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association
Samar R. El Khoudary, Brooke Aggarwal, Theresa M. Beckie, et al.
Circulation (2020) Vol. 142, Iss. 25
Open Access | Times Cited: 615
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Peng Kong, Ziyang Cui, Xiao-Fu Huang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 598
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 597
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Steven E. Nissen, A. Michael Lincoff, Danielle M. Brennan, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 15, pp. 1353-1364
Closed Access | Times Cited: 539
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd‐Jones, Pamela B. Morris, Christie M. Ballantyne, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 14, pp. 1366-1418
Open Access | Times Cited: 305
Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
Josefin Soppert, Michael Lehrke, Nikolaus Marx, et al.
Advanced Drug Delivery Reviews (2020) Vol. 159, pp. 4-33
Open Access | Times Cited: 259
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics
Yajun Duan, Ke Gong, Suowen Xu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 249
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 9, pp. 833-955
Open Access | Times Cited: 224
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary
Yehuda Handelsman, Paul S. Jellinger, Chris Guerin, et al.
Endocrine Practice (2020) Vol. 26, Iss. 10, pp. 1196-1224
Closed Access | Times Cited: 203
ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review
Xiaojun Feng, Lei Zhang, Suowen Xu, et al.
Progress in Lipid Research (2019) Vol. 77, pp. 101006-101006
Closed Access | Times Cited: 192
Ten things to know about ten cardiovascular disease risk factors
Harold Bays, Pam R. Taub, Elizabeth Epstein, et al.
American Journal of Preventive Cardiology (2021) Vol. 5, pp. 100149-100149
Open Access | Times Cited: 176
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
Maciej Banach, P. Barton Duell, Antonio M. Gotto, et al.
JAMA Cardiology (2020) Vol. 5, Iss. 10, pp. 1124-1124
Open Access | Times Cited: 165
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
Raúl D. Santos, Andrea Ruzza, G. Kees Hovingh, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 14, pp. 1317-1327
Open Access | Times Cited: 150
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus, et al.
Archives of Medical Science (2021) Vol. 17, Iss. 6, pp. 1447-1547
Open Access | Times Cited: 133
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
Maurizio Averna, Maciej Banach, Éric Bruckert, et al.
Atherosclerosis (2021) Vol. 325, pp. 99-109
Closed Access | Times Cited: 118
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Marisa R. Morrow, Battsetseg Batchuluun, Jianhan Wu, et al.
Cell Metabolism (2022) Vol. 34, Iss. 6, pp. 919-936.e8
Open Access | Times Cited: 118
Role of Bempedoic Acid in Clinical Practice
Christie M. Ballantyne, Harold Bays, Alberico L. Catapano, et al.
Cardiovascular Drugs and Therapy (2021) Vol. 35, Iss. 4, pp. 853-864
Open Access | Times Cited: 114
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 84
2023 Chinese guideline for lipid management
Jian‐Jun Li, Shui‐Ping Zhao, Dong Zhao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
Nick S. Nurmohamed, Jordan M. Kraaijenhof, Manuel Mayr, et al.
European Heart Journal (2023) Vol. 44, Iss. 18, pp. 1594-1607
Open Access | Times Cited: 69
Understanding the molecular mechanisms of statin pleiotropic effects
Charles German, James K. Liao
Archives of Toxicology (2023) Vol. 97, Iss. 6, pp. 1529-1545
Open Access | Times Cited: 66
Acetylcarnitine shuttling links mitochondrial metabolism to histone acetylation and lipogenesis
Luke Izzo, Sophie Trefely, Christina Demetriadou, et al.
Science Advances (2023) Vol. 9, Iss. 18
Open Access | Times Cited: 56
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 5, pp. 477-495
Open Access | Times Cited: 46
Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial
Paul M. Ridker, Lei Lei, Kausik K. Ray, et al.
Journal of clinical lipidology (2023) Vol. 17, Iss. 2, pp. 297-302
Closed Access | Times Cited: 45
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Sunil V. Rao, Michelle L. O’Donoghue, Marc Ruel, et al.
Circulation (2025)
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top